Program Cuts Glucose Levels Among Its 14,000 Diabetes Patients With diabetes a national epidemic and the prevalence of the disease as high as 18 percent in the South Bronx, a unique physician "pay-for-performance" program at Montefiore Medical Center has reduced blood sugar and cholesterol levels significantly among many of this borough's diabetes population.
Source: www.medicalnewstoday.comLong-Term Reproductive Success Results From Exposing Chicks To Maternal Stress Do mothers purposely expose their offspring to their own stress? If so, why? The question arises because it is widely accepted that exposure to maternal stress during pre-natal development can have negative impacts on offspring following birth.
Source: www.medicalnewstoday.comNanomaterials May Have Large Environmental Footprint According To Yale Journal Environmental gains derived from the use of nanomaterials may be offset in part by the process used to manufacture them, according to research published in a special issue of the Journal of Industrial Ecology.
Source: www.medicalnewstoday.comMultiple Sclerosis Disease Activity Reduced After Taking Oral Fumarate An article published in The Lancet reports successful results from a phase II trial for oral fumarate (BG00012). The drug was found to significantly reduce disease activity linked to relapsing-remitting multiple sclerosis (RRMS) that was detected by Magnetic Resonance Imaging (MRI). A phase III trial is underway and the researchers are awaiting the results.
Source: www.medicalnewstoday.comDiabetics Learn From Doctors, Each Other, At Temple University Christopher Bailey used to be a boxer. He was scrappy, he says, but he was strong. He says he beat up guys twice his size. "Look at my face, no cuts or scars. My ears and eyes aren't messed up like some other fighters," he says. "I was careful. I learned everything I needed to know about each guy I went up against, and changed up my fighting to beat him.
Source: www.medicalnewstoday.comPTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements In Chloride Channel Function In Cystic Fibrosis Patients PTC Therapeutics, Inc. (PTC) announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation.
Source: www.medicalnewstoday.comAfter King-Drew Medical Center's Closure Trauma Deaths Decline At Harbor-UCLA Medical Center While the 2005 closure of King-Drew Medical Center's Level 1 trauma unit in Los Angeles County caused a 54 percent increase in trauma patients at nearby Harbor-UCLA Medical Center, the deaths among those patients actually declined, according to a new study published in this month's The American Surgeon.
Source: www.medicalnewstoday.comDoctor Criticizes NHS Choice Of Cervarix Over Gardasil For HPV A doctor expressed his opinions regarding the human papillomavirus (HPV) vaccination chosen by the United Kingdom for its immunization program, according to an opinion piece released on October 24, 2008 in BMJ. A general practitioner and and broadcaster, Phil Hammond claims that even doctors will choose Gardasil for their own children over the government's choice, Cervarix.
Source: www.medicalnewstoday.comAlcohol: A Life Sentence Every year, almost 4000 babies in Germany are born with alcohol-related defects. The mothers of these children have often drunk alcohol regularly during the pregnancy. The consequences are often devastating and commonly persist into adulthood.
Source: www.medicalnewstoday.comMinster Pharmaceuticals Plc Announces Positive Results From Phase II Trial Of Migraine With Aura Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo.
Source: www.medicalnewstoday.com
# posted by Network @ 2:00 PM
